ArticleOncoTargets and therapy2016
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.Scientific reports · 2018Trial
- Alteration of tumor characteristics following neoadjuvant treatment in gastric adenocarcinoma: a case report.Frontiers in oncology · 2026Article
- Perioperative serplulimab‑based chemoimmunotherapy in stage IV large cell neuroendocrine carcinoma of the lung: A case report.Oncology letters · 2024Article
- Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy-A Systematic Review.Cancers · 2023Review
- A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.Journal of clinical medicine · 2023Review
- Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis.Cancer medicine · 2023Article
- Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?Journal of clinical medicine · 2022Review
- Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.Journal for immunotherapy of cancer · 2021Article
- Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.Endocrine connections · 2021Article
- Identification of HOXD10 as a Marker of Poor Prognosis in Glioblastoma Multiforme.OncoTargets and therapy · 2021Article
- Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?Frontiers in endocrinology · 2021Review
- Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.Frontiers in oncology · 2021Review
- PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.Pathology oncology research : POR · 2020Review
- Neuroendocrine tumours and their microenvironment.Cancer immunology, immunotherapy : CII · 2020Article
- Novel immunotherapy strategies for treatment of neuroendocrine neoplasms.Translational gastroenterology and hepatology · 2020Review
- PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.Endocrine connections · 2019Article
- Article
- Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.World journal of gastroenterology · 2019Article
- FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.Journal of cancer research and clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProgrammed death 1 (PD-1) receptor and its ligand, programmed death ligand-1 (PD-L1), play critical roles in the immune invasion of various tumors. This study aimed to explore the clinical significance of PD-L1/PD-1 expression in the progression of pulmonary neuroendocrine tumors (PNETs).
methodsThe expression of PD-L1 and PD-1 in 80 patients diagnosed with PNETs were investigated. Immunohistochemical analysis was performed on 80 formalin-fixed paraffin-embedded tissue specimens from PNETs and 20 corresponding cancer-adjacent tissue specimens.
resultsTissues from PNETs had higher levels of PD-L1 (58.8%) and PD-1 (51.3%) compared to the cancer-adjacent tissues (25% and 20%, respectively). Meanwhile, PD-L1 expression was associated with PD-1 expression (
conclusionData suggested that PD-L1 and PD-1 can be useful prognostic biomarkers for survival and can pave the way toward new immunotherapy regimens against PNETs through targeting the PD-L1/PD-1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.